Established in 2019, Lanterne Dx’s 4500 sf laboratory is a state-of-the-art facility equipped to meet your end-to-end research needs. Lanterne Dx (LDX) is a full-service histopathology CRO offering discovery, translational, and clinical biomarker services. As a CAP-CLIA accredited provider, LDX specializes in biomarker development, including antibody development, optimization, and validation. Key capabilities include immunohistochemistry (IHC), immunofluorescence (IF), multiplexing, in situ hybridization (ISH), fluorescence in situ hybridization (FISH), and a wide range of microscopic applications. These services are complemented by both qualitative and quantitative pathology evaluations, advanced image analysis, and comprehensive data analysis—all designed to streamline and accelerate drug development efforts.
At Lanterne Dx, we are dedicated to being your trusted partner throughout the drug development journey, offering expert guidance from preclinical research to translational studies and into clinical applications.